Full-Time

Manager – Accounting

Posted on 12/2/2025

Integer Holdings Corporation

Integer Holdings Corporation

1,001-5,000 employees

Medical device CDMO for cardiac devices

Compensation Overview

$97.5k - $143k/yr

Corfu, NY, USA

In Person

Category
Accounting (2)
,
Required Skills
Power BI
Risk Management
Oracle
Requirements
  • Minimum Education: BS Accounting or Finance; CPA preferred.
  • Minimum Experience: 4+ years experience in public accounting or 7+ years accounting experience required; 2+ years leadership experience preferred; Technical accounting experience strongly preferred; Experience in a large ERP manufacturing environment strongly preferred; Experience in a multi-national manufacturing organization strongly preferred.
  • Knowledge & Skills: Special Skills: Strong leadership, communication (verbal/written), and interpersonal skills a must; Ability to work collaboratively and communicate technical accounting standards across different organizational levels, including Senior Management; Strong planning, organizational, project management, process improvement, and analytical skills; Demonstrated ability to work and draw conclusions independently within rigid deadlines is essential; Management of self’s and team’s multiple competing tasks, demands, and priorities in a fast-paced working environment is essential.; Experience effectively managing and leading a team in a virtual environment and with business partners across multiple functions and geographic regions.
  • Specialized Knowledge: Strong working knowledge of SOX, U.S. GAAP, and related financial statement preparation; Experience with manufacturing ERP systems is required; Oracle and Hyperion experience preferred; Deep knowledge of Microsoft applications, including MS Office, Power BI & MS Teams preferred.
Responsibilities
  • Adheres to Integer’s Values and all safety, environmental, security and quality requirements including, but not limited to: Quality Management Systems (QMS), Safety, Environmental and Security Management Systems, U.S. Food and Drug Administration (FDA) regulations, company policies and operating procedures, and other regulatory requirements.
  • Performs procedures to ensure the revenue cycle is in full compliance with SOX requirements.
  • Develops and implements policies and procedures for revenue and revenue related transactions to ensure appropriate application of U.S. GAAP and completeness and accuracy of financial information.
  • Reviews and analyzes all contracts with customers to ensure appropriate application of U.S. GAAP, specifically ASC 606.
  • Manages and oversees the daily responsibilities of assigned staff members, including, but not limited to, analysis of engineering revenue transactions, calculation of rebates and other price concessions, calculation of royalty payments, performance of cut-off procedures, and recognition of over time production revenue.
  • Reviews and approves relevant calculations, journal entries, and general ledger account reconciliations for accuracy and completeness and timely completion within established monthly period-end close deadlines.
  • Collaborates with Customer Success, Financial Planning & Analysis, Commercial Finance, Legal, Sales and other finance and business leaders on unique revenue transactions.
  • Provides guidance on Company’s negotiations with customers related to revenue-generating contracts.
  • Reviews calculations impacting revenue related financial statement line items prepared by Commercial Finance or other finance functions.
  • Prepares and presents revenue and revenue related internal reports on a periodic basis to senior finance and accounting leadership.
  • Reviews revenue and revenue-related disclosures for the Company’s SEC filings.
  • Researches and analyzes general ledger accounts to provide answers to accounting related inquiries.
  • Remains current on recent changes in technical accounting guidance affecting revenue and provides training and guidance to team members and others, as well as implements changes to existing policies and procedures, as needed.
  • Leads revenue related integration efforts for new mergers or acquisitions, including gaining an understanding of the acquiree’s revenue policies, procedures and transactions, identifying differences with Integer’s policies and procedures and developing and implementing necessarily integration plans to align the acquiree with Integer standard procedures and policies, all within internal and external deadlines.
  • Reviews source documents as required to make appropriate accounting determinations.
  • Prepares and reviews various accounting reports, schedules and analyses which support business decisions.
  • Adheres to and ensures compliance of all internal and external financial reporting deadlines for self and team.
  • Demonstrates creation of a collaborative group environment of continuous improvement and achievement of best practices.
  • Hires, trains, disciplines, and appraises performance of direct reports, including completion and communication of annual performance evaluations, bonus and merit.
  • Approves Associate PTO requests to ensure adequate staffing.
  • Provides guidance and recommendations and actively participates in implementation of new technologies impacting revenue and revenue related transactions.
  • Performs other duties as required.
Integer Holdings Corporation

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Simplify Jobs

Simplify's Take

What believers are saying

  • Board initiated strategic review on April 30, 2026, exploring sale options.
  • Irenic Capital acquired $99M stake in Q4 2025 as top holding.
  • $200M share repurchase authorization signals management confidence in valuation.

What critics are saying

  • Class action lawsuits by Pomerantz and Bleichmar drain cash via settlements by Q4 2026.
  • Three new products cause 3-4% headwind, slashing H2 2026 margins.
  • Irenic activism forces sale at depressed valuation below $93 target in 12 months.

What makes Integer Holdings Corporation unique

  • Integer specializes in contract manufacturing for Cardio & Vascular medical devices.
  • Organic revenue grew 1.3% in Q1 2026 despite flat overall sales.
  • Robust pipeline targets above-market growth by 200 basis points in 2027.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Adoption Assistance

Parental Leave

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 24th, 2026
Integer VP sells $70K in shares as stock drops 28% in a year

Integer Holdings Corporation shares fell 28% following an insider sale disclosure. Tom Thomas, the company's vice president and corporate controller, sold 825 shares of common stock in an open-market transaction on 13 March 2026, according to an SEC Form 4 filing. The transaction was valued at $70,000 at a reported price of $85 per share. The sale represented 15.85% of Thomas's direct holdings at the time. Following the transaction, Thomas holds 4,380 shares worth approximately $364,000. This marks Thomas's third open-market sale since 2018, following previous sales of 884 shares in November and 1,500 shares in April. Integer Holdings manufactures medical devices and components, generating $1.85 billion in trailing twelve-month revenue.

Yahoo Finance
Feb 26th, 2026
Integer Holdings Q4 earnings beat forecasts on strong Cardio & Vascular demand

Integer Holdings, a medical device manufacturer, reported fourth quarter revenue of $472.1 million and adjusted earnings per share of $1.76, both exceeding analyst expectations. The company posted 5% year-on-year revenue growth, driven by strong performance in its Cardio & Vascular segment. CEO Peyman Khales attributed $30 million in operational improvements to higher sales volume, manufacturing efficiencies and expense management. The company guided adjusted earnings per share of $6.54 for 2026, beating analyst estimates by 3.8%. During the earnings call, analysts questioned the narrowing of organic sales guidance, first quarter margin compression and the company's path to above-market growth in 2027. Management emphasised collaborative customer planning and reaffirmed its current strategy despite activist investor involvement.

Intellectia.AI
Feb 23rd, 2026
Irenic Capital takes $99M stake in Integer Holdings as medical device firm posts 8% sales growth

Irenic Capital Management has acquired a $99.11 million stake in Integer Holdings, purchasing 1,263,663 shares in Q4 2026. The position represents 13.7% of Irenic's assets under management, making it the fund's largest disclosed equity holding. Integer Holdings, a medical device company, achieved 8% sales growth in 2025, reaching $1.85 billion in revenue, with adjusted earnings per share rising 21% to $6.40. The company reported fourth-quarter sales of $472 million and net income of $62 million, up 22% year-over-year. Management projects 2026 adjusted earnings per share between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027. Benchmark analyst Robert Wasserman upgraded the stock from hold to buy with a $95 price target.

Yahoo Finance
Feb 23rd, 2026
Integer posts 21% adjusted EPS growth but warns of H1 2026 headwinds from slower product adoption

Integer Holdings reported strong 2025 results with sales up 8% and adjusted earnings per share rising 21% to $6.40, alongside margin expansion and $105 million in free cash flow. The company returned capital through a $50 million share repurchase and announced an additional $50 million accelerated share repurchase programme. However, management warned that three newer products representing approximately 6% of 2025 sales are experiencing slower-than-expected adoption, creating a 3%–4% headwind for 2026. The company expects flat-to-slightly-down sales and a 200–250 basis point hit to first-quarter operating margin, with recovery and margin expansion anticipated in the second half. Integer maintained its 2026 midpoint guidance, with year-end net debt expected at $1.17–1.19 billion and net leverage remaining at 3.0 times adjusted EBITDA.

Yahoo Finance
Feb 19th, 2026
Integer faces 2026 headwinds from delayed product launches despite $200M buyback and robust pipeline

Integer Holdings, a medical device contract manufacturing organisation, reported fourth-quarter sales of $472 million, up 5% year-over-year, with adjusted earnings per share at the high end of its October guidance range. For the full year 2025, sales increased 8% on a reported basis and over 6% organically, whilst adjusted operating income rose 13%. The company issued 2026 guidance expecting reported sales to be down 1% to up 1%, with a 3% to 4% headwind from three new products facing lower-than-expected market adoption. However, Integer's underlying business is expected to grow 4% to 6%, in line with the market. Integer repurchased $50 million of shares in Q4 and announced plans for an additional $50 million accelerated share repurchase programme under its $200 million authorisation.

INACTIVE